Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Patients"Opinions Should Be Reflected in Evaluation of Generics: Prof. Yanagawa
March 20, 2006
- Kyowa Hakko Completes PIII Trials of Parkinson's Treatment KW-6002
March 20, 2006
- JammNet Publishes Generic Market Share Report for 2005
March 20, 2006
- Kyorin Starts PI Study of New Diabetes Treatment in the US
March 20, 2006
- JMA to Hold 27th General Assembly April 5-8 in Osaka
March 20, 2006
- New Drug Applications Declined in 2005: OPIR Survey
March 20, 2006
- Use of Anti-allergy Drugs by GPs Surveyed by JMDC
March 20, 2006
- Slow Clinical Trials Delaying Domestic Launch of New Drugs
March 20, 2006
- New NHI Prices Announced: Anti-ulcer Drugs See 10.5% Price Cut
March 20, 2006
- PMDA to Provide More Consultations by Streamlining Its Operation
March 20, 2006
- Sanofi-aventis Readying for Launch of Plavix
March 20, 2006
- Public Symposium Focuses on Cancer Diagnosis and Treatment
March 20, 2006
- STATISTICS
March 20, 2006
- SEMINAR
March 20, 2006
- Major Products, Major Firms Hit Hard: NHI Price Revision
March 20, 2006
- HUMAN RESOURCES
March 20, 2006
- Industry Must Reject Price Reductions Not Based on Market Prices: JPMA President
March 20, 2006
- Pharmacies to Play a Greater Role: JPA Vice President
March 20, 2006
- Takeda Asks Wholesalers Not to Accept Proposals of Bundling from Pharmacy Chains
March 20, 2006
- JPA Presents Petition Regarding New OTC Drug Marketing System
March 20, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…